Eli Lilly partners with Alzheimer's center for PhIII study; New tuberculosis consortium emerges in $218M+ project
As Eli Lilly preps to submit its Alzheimer’s candidate donanemab to the FDA following Biogen’s Aduhelm approval, the Big Pharma is working to collaborate with a Phoenix research institute to advance the program’s Phase III study.
Lilly will team up with the Banner Alzheimer’s Institute to see whether donanemab can slow clinical progression, the company announced Thursday. Banner will support the enrollment of trial participants with and without the e4 type of apolipoprotein E.
“This collaboration combines Lilly’s more than 30 years of dedication to Alzheimer’s research with Banner’s unique expertise and showcases our collective commitment to partner within the health care community to find potential treatments to end this devastating disease,” said Lilly chief of pain and neurodegeneration Mark Mintun in a statement.
Enrollment of the study is planned for later this year.
Lilly announced its plans to submit the donanemab only a few weeks after the controversial accelerated approval for Biogen’s drug. Like Aduhelm, donanemab aims to clear amyloid from the brain. Last month’s green light indicated at least some regulators consider amyloid clearance reasonably likely to lead to cognitive benefit.
New tuberculosis consortium comes together in $218M+ project
A new collaboration to fight tuberculosis has launched in the Netherlands, and it’s picked up a hefty heaping of cash.
Unite4TB is starting off with a seven-year, $218.6 million project to advance research for the deadly disease, the group announced Thursday. The goal is to fund clinical research for new drugs and potential combinations of existing medicines to work against drug-resistant and drug-sensitive tuberculosis.
“By bringing together leading experts from the public and private sectors in Europe and beyond, UNITE4TB is well placed to deliver results that will accelerate the development of better treatment regimens to tackle this disease,” Pierre Meulien, executive director of the incubator that launched the collaboration, said in a statement.
The consortium has brought together 30 companies from 13 different countries in its effort.